deltatrials
Terminated PHASE2 NCT00219908

Evaluation of a New Therapeutic Strategy in Early and Active Relapsing-Remitting Multiple Sclerosis

Evaluation of a New Therapeutic Strategy in Early and Active Relapsing-Remitting Multiple Sclerosis: Induction Treatment With Mitoxantrone Followed by Long-Term Treatment With Interferon-beta1b

Sponsor: Bayer

Conditions Relapsing-Remitting Multiple Sclerosis
Interventions Mitoxantrone
Updated 6 times since 2017 Last updated: Dec 21, 2005 Started: Jul 31, 1999 Completion: Jun 30, 2006

Listed as NCT00219908, this PHASE2 trial focuses on Relapsing-Remitting Multiple Sclerosis and remains terminated or withdrawn. Sponsored by Bayer, it has been updated 6 times since 1999, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Terminated PHASE2

    First recorded

Jul 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bayer
  • Farmades, Italy
  • Rennes University Hospital
  • Wyeth is now a wholly owned subsidiary of Pfizer
Data source: Rennes University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bari, Italy, Caen, France, Clermont-Ferrand, France, Créteil, France, Dijon, France, Florence, Italy, Gallarate, Italy, Genova, Italy, Limoges, France, Lomme, France and 10 more location s